Update on primary immunodeficiency: Defects of lymphocytes

Clinical Immunology

Volumn 109, Issue 2, 2003, Pages 109-118

  Simonte, Steven J ^a   Cunningham Rundles, Charlotte ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody deficiency; Primary immune deficiency; Severe combined immunodeficiency; T cell activation defects

Indexed keywords

ADENOSINE DEAMINASE; ALPHA FETOPROTEIN; ANTIBIOTIC AGENT; ANTIBODY; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BRUTONS TYROSINE KINASE; CASPASE 10; CD4 ANTIGEN; CYCLOSPORIN; CYTIDINE DEAMINASE; CYTOKINE; DNA TOPOISOMERASE INHIBITOR; DOUBLE STRANDED DNA; FAS LIGAND; GENE PRODUCT; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN TYROSINE KINASE; RECOMBINASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; T LYMPHOCYTE RECEPTOR; TACROLIMUS; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; AUTOIMMUNITY; AUTOSOMAL RECESSIVE DISORDER; B LYMPHOCYTE; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CELL DAMAGE; CELL FUNCTION; CELL MATURATION; CHROMOSOME DELETION; CHRONIC INFLAMMATION; CLINICAL FEATURE; COMBINED IMMUNODEFICIENCY; COMMON VARIABLE IMMUNODEFICIENCY; DIGEORGE SYNDROME; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE IDENTIFICATION; GENE LOCATION; GENE LOCUS; GENE MUTATION; GENE THERAPY; GENETIC DISORDER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; IMMUNIZATION; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN PRODUCTION; INFECTION PREVENTION; LEUKEMIA; LYMPH NODE HYPERPLASIA; LYMPHOCYTE; MORBIDITY; MORTALITY; MYCOBACTERIOSIS; NATURAL KILLER CELL; OPPORTUNISTIC INFECTION; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; RNA EDITING; SIGNAL TRANSDUCTION; SOMATIC HYPERMUTATION; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; WISKOTT ALDRICH SYNDROME; X LINKED AGAMMAGLOBULINEMIA;

EID: 0242270832     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6616(03)00183-9     Document Type: Short Survey

References (131)

1. Sorensen R.U., Moore C. Antibody Deficiency Syndromes. Fleisher T.A., Ballow M. Pediatric Clinics of North America. 2000;1225-1252 Saunders, Philadelphia.
2. Bruton O.C. Agammaglobulinemia. Pediatrics. 9:1952;722-727.
3. Vetrie D., Vorechovsky I., Sideras P., Holland J., Davies A., Flinter F., et al. The gene involved in X-linked agammaglobulinemia is a member of the Src family of protein-tyrosine kinases. Nature. 361:1993;226-233.
4. Tsukada S., Saffran D.C., Rawlings D.J., Parolini O., Allen R.C., Klisak I., et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 72:1993;279-290.
5. Conley M.E., Mathias D., Treadaway J., Minegishi Y., Rohrer J. Mutations in Btk in patients with presumed X-linked agammaglobulinemia. Am. J. Hum. Genet. 62:1998;1034-1043.
6. Wood P., Smith E., Hazelwood M., Joyce H., Granoff D., Kumararatne D. Atypical Btk deficiency presenting with selective polysaccharide deficiency in the presence of normal serum immunoglobulins (abstract). J. Allergy Clin. Immunol. 105:2000;S219.
7. Plebani A., Soresina A., Rondelli R., Amato G.M., Azzari C., Cardinale F., et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia an Italian multicenter study . Clin. Immunol. 104:2002;221-230.
8. Conley M.E., Howard V. Clinical findings leading to the diagnosis of X-linked agammaglobulinemia. J. Pediatr. 141:2002;566-571.
9. Conley M.E., Notarangelo L.D., Etzioni A. Diagnostic criteria for primary immunodeficiencies. Clin. Immunol. 93:1999;190-197.
10. Yel L., Minegishi Y., Coustan-Smith E., Buckley R.H., Trubel H., Pachman L.M., et al. Mutations in mu heavy-chain gene in patients with agammaglobulinemia. N. Engl. J. Med. 335:1996;1486-1493.
11. Lopez Granados E., Porpiglia A.S., Hogan M.B., Matamoros N., Krasovec S., Pignata C., et al. Clinical and molecular analysis of patients with defects in micro heavy chain gene. J. Clin. Invest. 110:2002;1029-1035.
12. Minegishi Y., Coustan-Smith E., Wang Y.H., Cooper M.D., Campana D., Conley M.E., et al. Mutations in the human lambda5/14.1 gene result in B cell deficiency and agammaglobulinemia. J. Exp. Med. 187:1998;71-77.
13. Wang Y., Kanegane H., Sanal O., Tezcan I., Ersoy F., Futatani T., et al. Novel Igalpha (CD79a) gene mutation in a Turkish patient with B cell deficient agammaglobulinemia. Am. J. Med. Genet. 108:2002;333-336.
14. Minegishi Y., Coustan-Smith E., Rapalus L., Ersoy F., Campana D., Conley M.E. Mutations in Igalpha (CD79a) result in a complete block in B cell development. J. Clin. Invest. 104:1999;1115-1121.
15. Minegishi Y., Rohrer J., Coustan-Smith E., Lederman H.M., Pappu R., Campana D., et al. An essential role for BLNK in human B cell development. Science. 286:1999;1954-1957.
16. Revy P., Muto T., Levy Y., Geissmann F., Plebani A., Sanal O., et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2). Cell. 102:2000;565-575.
17. Minegishi Y., Lavoie A., Cunningham-Rundles C., Bedard P.M., Hebert J., Cote L., et al. Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome. Clin. Immunol. 97:2000;203-210.
18. Levy J., Espanol-Boren T., Thomas C., Fischer A., Tovo P., Bordigoni P., et al. The clinical spectrum of X-linked hyper-IgM syndrome. J. Pediatr. 131:1997;47-54.
19. Ballow M. Primary immunodeficiency disorders antibody deficiency . J. Allergy Clin. Immunol. 109:2002;581-591.
20. Fasth A. Primary immunodeficiency disorders in Sweden cases among children, 1974-1979 . J. Clin. Immunol. 2:1982;86-92.
21. Primary immunodeficiency diseases. Clin. Exp. Immunol. 118:1999;1-34.
22. Clin. Exp. Immunol. 109:(Suppl. 1):1997;1-28.
23. Cunningham-Rundles C., Bodian C. Common variable immunodeficiency clinical and immunological features of 248 patients . Clin. Immunol. 92:1999;34-48.
24. Spickett G.P. Current perspectives on common variable immunodeficiency (CVID). Clin. Exp. Allergy. 31:2001;536-542.
25. Y. Levy, N. Gupta, F. LeDeist, C. Garcia, A. Fischer J.C. Weill, C.A. Reynaud, Defect in IgV gene somatic hypermutation in common variable immunodeficiency syndrome, 95 (1998) 13135-13140.
26. -) in subgroups of patients with common variable immunodeficiency a new approach to classify a heterogeneous disease . Blood. 99:2002;1544-1551.
27. Stagg A.J., Funauchi M., Knight S.C., Webster A.D.B., Farrant J. Failure in antigen responses by T cells from patients with common variable immunodeficiency (CVID). Clin. Exp. Immunol. 96:1994;48-53.
28. Kondratenko I., Amlot P.L., Webster A.D., Farrant J. Lack of specific antibody response in common variable immunodeficiency (CVID) associated with failure in production of antigen-specific memory T cells. Clin. Exp. Immunol. 108:1997;9-13.
29. G. Pastorelli, M.G. Roncarolo, J.L., J.L. Touraine, G. Peronne, P.A. Tovo, J.E. DeVries, Peripheral blood lymphocytes of patients with common variable immunodeficiency produce reduced levels of interleukin-4, interleukin-2 and interferon-gamma, but proliferate normally upon activation with mitogens, Clin. Exp. Immunol. 78 (1989) 334-340.
30. Sneller M.C., Strober W. Abnormalities of lymphokine gene expression in patients with common variable immunodeficiency. J. Immunol. 144:1990;3762-3769.
31. Grimbacher B., Hutloff A., Schlesier M., Glocker E., Warnatz K., Dräger R., et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat. Immunol. 4:2003;261-268.
32. Cunningbam-Rundles C. Physiology of IgA and IgA deficiency. J. Clin. Immunol. 21:2001;303-309.
33. Bjorkander J., Bake B., Ozelius V., Hanson L. Impaired lung function in patients with IgA deficiency and low levels of IgG2 or IgG3. N. Engl. J. Med. 313:1985;720-724.
34. Sandler S.G., Trimble J., Mallory D.M. Coexistent IgG2 and IgA deficiencies in blood donors. Transfusion. 36:1996;256-258.
35. Bonilla F.A., Geha R.S. Primary immunodeficiency diseases. J. Allergy Clin. Immunol. 111:(Suppl.):2003;S571-581.
36. Tiller T., Buckley R. Transient hypogammaglobulinemia of infancy review of the literature, clinical and immunologic features of 11 new cases, and long-term follow-up . J. Pediatr. 92:1978;347-353.
37. Ambrosino D.M., Siber G.R., Chilmonczyk B.A., Jernberg J.B., Finberg R.W. An immunodeficiency characterized by impaired antibody responses to polysaccharides. N. Engl. J. Med. 316:1987;790-793.
38. Buckley R.H., Schiff R.I., Schiff S.E., Markert M.L., Williams L.W., Harville T.O., et al. Human severe combined immunodeficiency genetic, phenotypic, and functional diversity in one hundred eight infants . J. Pediatr. 130:1997;378-387.
39. Fischer A. Severe combined immunodeficiency (SCID). Clin. Exp. Immunol. 122:2000;143-149.
40. Fischer A. Primary immunodeficiency diseases an experimental model for molecular medicine . Lancet. 357:2001;1863-1869.
41. Buckley R.H. Primary cellular immunodeficiencies. J. All. Clin. Immunol. 109:2002;747-757.
42. Buckley R.H. Advances in the understanding and treatment of human severe combined immunodeficiency. Immunol. Res. 22:2001;237-251.
43. Buckley R.H., Schiff S.E., Schiff R.I., Markert L., Williams L.W., Roberts J.L., et al. Hematopoietic stem cell transplantation for the treatment of severe combined immunodeficiency. N. Engl. J. Med. 340:1999;508-516.
44. Puck J.M., Deschenes S.M., Porter J.C., Dutra A.S., Brown C.J., Willard H.F., et al. The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1. Hum. Mol. Genet. 2:1993;1099-1104.
45. Noguchi M., Yi H., Rosenblatt H.M., Filipovich A.H., Adelstein S., Modi W.S., et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 73:1993;147-157.
46. Puck J.M. IL2RGbase a database of gamma c-chain defects causing human X-SCID . Immunol. Today. 17:1996;506-511.
47. Hacein-Bey-Abina S., von Kalle C., Schmidt M., Le Deist F., Wulffraat N., Mclntyre E., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency (correspondence). N. Engl. J. Med. 348:2003;255-256.
48. Notarangelo L.D., Giliani S., Mazza C., Mella P., Savoldi G., Rodriguez-Perez C., et al. Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency defects of the gamma(c)-JAK3 signaling pathway as a model . Immunol. Rev. 178:2000;39-48.
49. Puel A., Ziegler S.F., Buckley R.H., Leonard W.J. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat. Genet. 20:1998;394-397.
50. Roifman C.M., Zhang J., Chitayat D., Sharfe N. A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. Blood. 96:2000;2803-2807.
51. Hirschorn R. Immunodeficiency disease due to deficiency of adenosine deaminase. Ochs H.D., Smith C.I.E., Puck J.M. Primary Immunodeficiency Diseases. 1999;121-139 Oxford Univ. Press, New York.
52. Markert M.L. Purine nucleoside phosphorylase deficiency. Immunodef. Rev. 3:1991;45-81.
53. Schwarz K., Gauss G.H., Ludwig L., Pannicke U., Li Z., Lindner D., et al. RAG mutations in human B cell-negative SCID. Science. 274:1996;97-99.
54. Villa A., Santagata S., Bozzi F., Giliani S., Frattini A., Imberti L., et al. Partial V(D)J recombination activity leads to Omenn syndrome. Cell. 93:1998;885-896.
55. Villa A., Sobacchi C., Notarangelo L.D., Bozzi F., Abinun M., Abrahamsen T.G., et al. V(D)J recombination defects in lymphocytes due to RAG mutations severe immunodeficiency with a spectrum of clinical manifestations . Blood. 97:2001;81-88.
56. Brooks E.G., Filipovich A.H., Padgett J.W., Mamlock R., Goldblum R.M. T-cell receptor analysis in Omenn's syndrome evidence for defects in gene rearrangement and assembly . Blood. 93:1999;242-250.
57. Moshous D., Callebut I., de Chasseval R., Corneo B., Cavazzana-Calvo M., Le Deist F., et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immunodeficiency. Cell. 105:2001;177-186.
58. Nicolas N., Moshous D., Cavazzana-Calvo M., Papadopoulo D., de Chasseval R., Le Deist F., et al. A human severe combined immunodeficiency (SCID) condition with increased sensitivity to ionizing radiation and impaired V(D)J rearrangements defines a new DNA recombination/repair deficiency. J. Exp. Med. 188:1998;627-634.
59. Kwong P.C., O'Marcaigh A.S., Howard R., Cowan M.J., Frieden I.J. Oral and genital ulceration a unique presentation of immunodeficiency in Athabascan-speaking American Indian children with severe combined immunodeficiency . Arch. Dermatol. 135:1999;927-931.
60. Tchilian E.Z., Wallace D.L., Wells R.S., Flower D.R., Morgan G., Beverley P.C. A deletion in the gene encoding the CD45 antigen in a patient with SCID. J. Immunol. 166:2001;1308-1313.
61. Thoenes G., Soudias C., Le Deist F., Griscelli C., Fischer A., Lisowkska-Grospierre B. Structural analysis of low TCR-CD3 complex expression in T cells of an immunodeficient patient. J. Biol. Chem. 267:1992;487-493.
62. Amaiz-Villena A., Timon M., Correll A., Perez-Aciego P., Martin-Villa J.M., Regueiro J.R. Brief report primary immunodeficiency caused by mutations in the gene encoding the CD3-g subunit of the T lymphocyte receptor . N. Engl. J. Med. 327:1992;529-533.
63. Elder M.E. Severe combined immunodeficiency due to a defect in the tyrosine kinase ZAP-70. Pediatr. Res. 39:1996;743-748.
64. Sharfe N., Arpaia E., Roifman C.M. CD8 Lymphocytopenia caused by ZAP-70 deficiency. Roifman C.M. Immunology and Allergy Clinics of North America. 2000;77-95 W.B. Saunders, Philadelphia.
65. de la Salle H., Zimmer J., Fricker D., Angenieux C., Cazenave J.P., Okubo M., et al. HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. J. Clin. Invest. 103:1999;R9-13.
66. Gadola S.D., Moins-Teisserenc H.T., Trowsdale J., Gross W.L., Cerundolo V. TAP deficiency syndrome. Clin. Exp. Immunol. 121:2000;173-178.
67. Zhou H., Glimcher L.H. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency. Immunity. 2:1995;545-553.
68. Masternak K., Barras E., Zufferey M., Conrad B., Corthals G., Aebersold R., et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat. Genet. 20:1998;273-277.
69. Steimle V., Durand B., Barras E., Zufferey M., Hadam M.R., Mach B., et al. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev. 9:1995;1021-1032.
70. Reith W., Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu. Rev. Immunol. 19:2001;331-373.
71. Villard J., Masternak K., Lisowska-Grospierre B., Fischer A., Reith W. MHC class II deficiency a disease of gene regulation . Medicine. 80:2001;405-418.
72. Döffinger R., Depuis S., Picard C., Fieschi C., Feinberg J., Barcenas-Morales G., Casanova J.L. Inherited disorders of IL-12-and IFNγ-mediated immunity a molecular genetics update . Mol. Immunol. 38:2001;903-909.
73. Picard C., Fieschi C., Altare F., Al-Jumaah S., Al-Hajjar S., Feinberg J., et al. Inherited interleukin-12 deficiency IL12B genotype and clinical phenotype of 13 patients from six kindreds . Am. J. Hum. Genet. 70:2002;336-348.
74. Dorman S.E., Holland S.M. Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. J. Clin. Invest. 101:1998;2364-2369.
75. Sullivan K.E. DiGeorge syndrome/chromosome 22q11 deletion syndrome. Curr. Allergy Asthma Rep. 1:2001;438-444.
76. Kornfeld S.J., Zeffren B., Christodoulou C.S., Day N.K., Cawkwell G.G., Good R.A. DiGeorge anomaly a comparative study of the clinical and immunologic characteristics of patients positive and negative by fluorescence in situ hybridization . J. Allergy Clin. Immunol. 105:2000;983-987.
77. Jawad A.F., McDonald-Mcginn D.M., Zackai E., Sullivan K.E. Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/ velocardiofacial syndrome). J. Pediatr. 139:2001;715-723.
78. Driscoll D.A., Sullivan K.E. DiGeorge syndrome a chromosome 22q11.2 deletion syndrome . Ochs H.D., Smith C.I.E., Puck J.M. Primary Immunodeficiency Diseases. 1999;198-208 Oxford Univ. Press, New York.
79. Markert M.L., Boeck A., Hale L.P., Kloster A.L., McLaughlin T.M., Batchvarova M.N., et al. Thymus transplantation in complete DiGeorge syndrome. N. Engl. J. Med. 341:1999;1180-1189.
80. Bonilla F.A., Geha R.S. CD154 deficiency and related syndromes. Roifman C.M. Immunology and Allergy Clinics of North America. 2001;65-89 Saunders, Philadelphia.
81. Durandy A., Honjo T. Human genetic defects in class-switch recombination (hyper-IgM syndromes). Curr. Opin. Immunol. 12:2001;543-548.
82. Hayward A.R., Levy L., Facchetti F., Notarangelo L., Ochs H.D.H.D., Etzioni A., et al. holangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J. Immunol. 158:1997;977-983.
83. Ferrari S., Giliani S., Insalaco A., Al-Ghonaium A., Sorensina A.R., Loubser M., et al. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc. Natl. Acad. Sci. USA. 98:2001;12614-12619.
84. Jain A., Ma C.A., Liu S., Brown M., Cohen J., Strober W. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat. Immunol. 2:2001;223-228.
85. Orange J.S., Brodeur S.R., Jain A., Bonilla F.A., Schneider L.C., Kretschmer R., et al. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J. Clin. Invest. 109:2002;1501-1509.
86. Zonana J., Elder M.E., Schneider L.C., Orlow S.J., Moss C., Golabi M., et al. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am. J. Hum. Genet. 67:2000;1555-1562.
87. Aradhya S., Woffendin H., Jakins T., Bardaro T., Esposito T., Smahi A., et al. A recurrent deletion in the ubiquitously expressed NEMO (IKK-gamma) gene accounts for the vast majority of incontinentia pigmenti mutations. Hum. Mol. Genet. 10:2001;2171-2179.
88. Ochs H.D., Rosen F.S. The Wiskott-Aldrich syndrome. Ochs H.D., Smith C.I.E., Puck J.M. Primary Immunodeficiency Diseases. 1999;292-305 Oxford Univ. Press, New York.
89. Ochs H.D. The Wiskott-Aldrich syndrome. Isr. Med. Assoc. J. 4:2002;379-384.
90. Symons M., Derry J.M., Karlak B., Jiang S., Lemahieu V., Mccormick F., et al. Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell. 84:1996;723-734.
91. Snapper S.B., Rosen F.S. The Wiskott-Aldrich syndrome protein (WASP) roles in signaling and cytoskeletal organization . Annu. Rev. Immunol. 17:1999;905-929.
92. Haddad E., Zugaza J.L., Louache F., Debili N., Crouin C., Schwarz K., et al. The interaction between Cdc42 and WASP is required for SDF-1-induced T-lymphocyte chemotaxis. Blood. 97:2001;33-38.
93. Zhu Q., Zhang M., Blaese R.M., Derry J.M., Junker A., Francke U., et al. The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene. Blood. 86:1995;3797-3804.
94. Devriendt K., Kim A.S., Mathijs G., Frints S.G., Schwartz M., Van Den Oord J.J., et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat. Genet. 27:2001;313-317.
95. Zhu Q., Watanabe C., Liu T., Hollenbaugh D., Blaese R.M., Kanner S.B., et al. Wiskott-Aldrich syndrome/X-linked thrombocytopenia WASP gene mutations, protein expression, and phenotype . Blood. 90:1997;2680-2689.
96. A.H. Filipovich, J.V. Stone, S.C. Tomany, M. Ireland, C. Kollman C., C.J. Pelz C.J., et al., Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program, Blood 97 (2001) 1598-1603.
97. Bleesing J.J.H., Strauss S.E., Fleisher T.A. Autoimmune lymphoproliferative syndrome a human disorder of abnormal lymphocyte survival . Fleisher T.A., Ballow M. Pediatric Clinics of North America. 2000;1291-1310 Saunders, Philadelphia.
98. Bleesing J.J.H. Autoimmune lymphoproliferative syndrome a genetic disorder of abnormal lymphocyte apoptosis . Sullivan K.E., Spergel J.M. Immunology and Allergy Clinics of North America. 2002;339-355 Saunders, Philadelphia.
99. Fisher G.H., Rosenberg F.J., Straus S.E., Dale J.K., Middleton L.A., Lin A.Y., et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 81:1995;935-946.
100. Infante A.J., Britton H.A., DeNapoli T., Middelton L.A., Lenardo M.J., Jackson C.E., et al. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis. J. Pediatr. 133:1998;629-633.
101. Jackson C.E., Fischer R.E., Hsu A.P., Anderson S.M., Choi Y., Wang J., et al. Autoimmune lymphoproliferative syndrome with defective Fas genotype influences penetrance . Am. J. Hum. Genet. 64:1999;1002-1014.
102. Straus S.E., Sneller M., Lenardo M.J., Puck J.M., Strober W. An inherited disorder of lymphocyte apoptosis the autoimmune lymphoproliferative syndrome . Ann. Intern. Med. 130:1999;591-601.
103. Sleight B.J., Prasad V.S., DeLaat C., Steele P., Ballard E., Arceci R.J., et al. Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation. Bone Marrow Transplant. 22:1998;375-380.
104. Purtilo D.T., Cassel C.K., Yang J.P., Harper R. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet. 1:1975;935-940.
105. Seemayer T.A., Gross T.G., Egeler R.M., Pirruccello S.J., Davis J.R., Kelly C.M., et al. X-linked lymphoproliferative disease twenty-five years after the discovery . Pediatr. Res. 38:1995;471-478.
106. Morra M., Howie D., Grande M.S., Sayos J., Wang N., Wu C., et al. X-linked lymphoproliferative disease a progressive immunodeficiency . Annu. Rev. Immunol. 19:2001;657-682.
107. Nichols K.E., Gross T.G. X-linked lymphoproliferative disease. Sullivan K.E., Spergel J.M. Immunology and Allergy Clinics of North America. 2002;319-337 Saunders, Philadelphia.
108. Sayos J., Wu C., Morra M., Wang N., Zhang X., Allen D., et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature. 395:1998;462-469.
109. Nagy N., Cerboni C., Mattsson K., Maeda A., Gogolak P., Sumegi J., et al. SH2D1A and SLAM protein expression in human lymphocytes and derived cell lines. Int. J. Cancer. 88:2000;439-447.
110. Tangye S.G., Phillips J.H., Lanier L.L., Nichols K.E. Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. J. Immunol. 165:2000;2932-2936.
111. Gross T.G., Filipovich A.H., Conley M.E., Pracher E., Schmiegelow K., Verdirame J.D., et al. Cure of X-linked lymphoproliferative disease (XLP) with allogeneic hematopoietic stem cell transplantation (HSCT) report from the XLP registry . Bone Marrow Transplant. 17:1996;741-744.
112. Aaltonen J., Bjorses P., Sandkuijl L., Perheentupa J., Peltonen L. An autosomal locus causing autoimmune disease autoimmune polyglandular disease type 1 assigned to chromosome 21 . Nat. Genet. 8:1994;83-87.
113. Aaltonen J., Bjorses P. Cloning of the APECED gene provides new insight into human autoimmunity. Ann. Med. 31:1999;111-116.
114. Bjorses P., Halonen M., Palvimo J.J., Kolmer M., Aaltonen J., Ellonen P., Perheentupa J., Ulmanen I., Peltonen L. Mutations in the AIRE gene effects on subcellular location and transactivation function of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protein . Am. J. Hum. Genet. 66:2000;378-392.
115. Kirkpatrick C.H. Chronic mucocutaneous candidiasis. Pediatr. Infect. Dis. J. 20:2001;197-206.
116. Lilic D. New perspectives on the immunology of chronic mucocutaneous candidiasis. Curr. Opin. Infect. Dis. 15:2002;143-147.
117. Bennett C.L., Yoshioka R., Kiyosawa H., Barker D.F., Fain P.R., Shigeoka A.O., et al. X-linked syndrome of polyendocrinopathy, immune dysfunction, and diarrhea maps to Xp11.23-Xq13.3. Am. J. Hum. Genet. 66:2000;461-468.
118. Bennett C.L., Ochs H.D. IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. Curr. Opin. Pediatr. 13:2001;533-538.
119. Ochs H.D., Khattri R., Bennett C.L., Brunkow M.E. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome and the scurfy mutant mouse. Sullivan K.E., Spergel J.M. Immunology and Allergy Clinics of North America. 2002;357-368 Saunders, Philadelphia.
120. Baud O., Goulet O., Canioni D., Le Deist F., Radford I., Rieu D., et al. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N. Engl. J. Med. 344:2001;1758-1762.
121. Regueiro J.R., Porras O., Lavin M., Gatti R.A. Ataxia-telangiectasia a primary immunodeficiency revisited . Roifman C.M. Immunology and Allergy Clinics of North America. 2000;177-206 Saunders, Philadelphia.
122. Carney J.P. Chromosomal breakage syndromes. Curr. Opin. Immunol. 11:1999;443-447.
123. Duker N.J. Chromosome breakage syndromes and cancer. Am. J. Med. Genet. 115:2002;125-129.
124. Lavin M.F., Shiloh Y. Ataxia-telangiectasia. Ochs H.D., Smith C.I.E., Puck J.M. Primary Immunodeficiency Diseases. 1999;306-323 Oxford Univ. Press, New York.
125. Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 268:1995;1749-1755.
126. Meyn M.S. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin. Genet. 55:1999;289-304.
127. Sandoval C., Swift M. Treatment of lymphoid malignancies in patients with ataxia-telangiectasia. Med. Pediatr. Oncol. 31:1998;491-497.
128. Nijmegen breakage syndrome. Arch. Dis. Child. 82:2000;400-406.
129. Varon R., Vissinga C., Platzer M., Cerosaletti K.M., Chrzanowska K.H., Saar K., et al. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell. 93:1998;467-476.
130. Carney J.P., Maser R.S., Olivares H., Davis E.M., Le Beau M., Yates J.R. 3rd, et al. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome linkage of double-strand break repair to the cellular DNA damage response . Cell. 93:1998;477-486.
131. Wu X., Ranganathan V., Weisman D.S., Heine W.F., Ciccone D.N., O'Neill T.B., et al. ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response. Nature. 405:2000;477-482.